CBT plus an SSRI was as effective as an SSRI alone for adolescents with moderate to severe depression: Commentary

Evidence-Based Medicine

Volumn 13, Issue 1, 2008, Pages 13-

  Goodyer, I ^a   Kutcher, Stan ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; CHILD HEALTH; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; FAMILY STRESS; HEALTH CARE DELIVERY; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT PARTICIPATION; PEER PRESSURE; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; TREATMENT DURATION;

EID: 39049155873     PISSN: 13565524     EISSN: None     Source Type: Journal    
DOI: 10.1136/ebm.13.1.13     Document Type: Short Survey

References (5)

1. March J, Silva S, Petrycki S. et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004;292:807-20.
2. The TADS Team. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007; 64:1132-43.
3. Hodes M, Garralda E. NICE Guideline on depression in children and young people: not always following the evidence. Psychiatric Bulletin 2007:31:361-2.
4. Sharp SC, Hellings JA. Efficacy and safety of selective serotonin reuptake inhibitors in the treatment of depression in children and adolescents: practitioner review. Clin Drug Investig 2006:26: 247-55
5. Kutcher S, Gardner D. SSRI use and youth suicide: making sense of a confusing story. Curr Opin Psychiatry [in press].